- Regulatory Status
- RUO
- Other Names
- B7H6, NCR3LG1, natural killer cell cytotoxicity receptor 3 ligand 1, B7 Homolog 6
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Quantity Check Availability | Save | ||
---|---|---|---|---|---|---|
568504 | 25 µg | 244€ | ||||
568506 | 100 µg | 728€ |
B7-H6 is a type I transmembrane protein and member of the B7 family. It contains 454 amino acids with a predicted molecular weight of 51 kDa and has several potential N-glycosylation sites. Similar to the other members of the B7 family, B7-H6 possesses two Ig like domains in the extracellular domain. The most related proteins to B7-H6 are B7-H1 and B7-H3. B7-H6 is expressed in human cancer cells such as myeloid and lymphoblastic leukemia, neuroblastomas, and melanomas, and it binds to NKp30 to activate human NK cells and target cell killing. Nevertheless, tumor cells can escape NK-cell-mediated recognition. A mechanism of immune escape involves tumor cell shedding of B7-H6. That process is mediated by ADAM10 and ADAM17. Thus, soluble B7-H6 high levels in blood have been detected in patients with malignant melanoma; levels that correlate with elevated B7-H6 expression in melanoma biopsies. In addition, B7-H6 is expressed in glioma stem-like cells derived from glioma cell lines in vitro. Soluble isoforms form of B7-H6 have also been detected in serum during normal pregnancy. These isoforms, of ∼37kDa and ∼30kDa, maintain the C- and N-terminus, and it seems that they are released by a mechanism different from proteolytic cleavage. B7-H6 can be induced in healthy cells by inflammatory process. B7-H6 and NKp30 orthologues do not exist in mice.
Product DetailsProduct Details
- Source
- Biotinylated recombinant human B7-H6, amino acid (Asp25-Ser262) (Accession # Q68D85.1), with a linker (IEGRMD), a C-terminal human IgG1 (Pro100-Lys330) and an Avi-tag, was expressed in CHO cells. Human B7-H6-Avi tag was site-specifically biotinylated by enzyme BirA.
- Molecular Mass
- The 490 amino acid recombinant protein has a predicted molecular mass of approximately 55.14 kD. The DTT-reduced and non-reduced protein migrates at approximately 65-115 kD and 140-240 kD by SDS-PAGE. The predicted N-terminal amino acid is Asp.
- Purity
- > 95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS, 5% glycerol and 2 mM EDTA
- Endotoxin Level
- Less than 0.1 EU per µg cytokine as determined by the LAL method.
- Concentration
- 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin the vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- When recombinant human NKp30 is immobilized at 1 µg/mL, biotinylated recombinant human B7-H6-Fc Chimera binds in a dose-dependent manner with ED50 of 2.5 – 15 ng/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Dimer
- Distribution
-
Human tumor cell lines, cancer cells, monocytes and neutrophils after inflammatory stimulation, glioma stem-like cells. Not detected in healthy cells
- Function
- Natural killer (NK) cell activation and cytotoxicity
- Interaction
- NK cells
- Ligand/Receptor
- NKp30 (CD337)
- Bioactivity
- When recombinant human NKp30 is immobilized at 1 µg/mL, biotinylated recombinant human B7-H6-Fc Chimera binds in a dose-dependent manner with ED50 of 2.5 – 15 ng/mL.
- Cell Type
- Leukemia, Monocytes, Neutrophils
- Biology Area
- Cancer Biomarkers, Cell Death, Immuno-Oncology, Immunology
- Antigen References
-
- Brandt CS, et al. 2009. J Exp Med. 206:1495-503.
- Kaifu T, et al. 2011. Cell Mol Life Sci. 68:3531-9.
- Matta J, et al. 2013. Blood. 122:394-404.
- Schlecker E, et al. 2014. Cancer Res. 74:3429-40.
- Chen Y, et al. 2018. Pathol Oncol Res. 24:717-721.
- Gutierrez-Franco J, et al. 2018. Immunobiology. 223:57-63.
- Obiedat A, et al. 2020. J Mol Med (Berl). 98:135-148.
- Chen H, et al. 2020. J Immunol Res. 2020:2328675.
- Gene ID
- 374383 View all products for this Gene ID
- UniProt
- View information about B7-H6 on UniProt.org
Follow Us